Bronchial Spasm Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Asthma and COPD Burden Creates a Durable Demand Floor

The bronchial spasm market benefits from sustained demand for long-term respiratory treatment. The World Health Organization stated in 2025 that more than 250 million people lived with asthma worldwide.^{[1]World Health Organization, “Chronic Obstructive Pulmonary Disease Fact Sheet,” World Health Organization, who.int.} Essential inhaled medicines remained unavailable in more than two-thirds of pharmacies and hospitals in low- and middle-income countries, limiting treatment access. Improved case finding and disease registries can expand the treated patient base, while the WHO European Region reported that global COPD cases are projected to increase by 23% between 2020 and 2050.

Shift Toward Combination and Long-Acting Bronchodilator Therapy Lifts Average Revenue Per Patient

The bronchial spasm market is shifting toward combination therapies for patients requiring stronger symptom control. The KALOS and LOGOS Phase 3 trials, published in February 2026, showed that budesonide, glycopyrronium, and formoterol improved trough FEV1 by 76 mL versus dual ICS-LABA therapy and reduced severe exacerbations by 14%.^{[2]Global Initiative for Asthma, “Increasing Access to Inhaled Medicines for COPD and Asthma,” Global Initiative for Asthma, ginasthma.org.} The American College of Chest Physicians issued a guideline on biologic management in severe asthma in January 2026, supporting structured treatment-switching decisions. These developments strengthen the commercial value of single-inhaler therapies that integrate medicines, device design, and clinical evidence.^{[3]American College of Chest Physicians, “Biologic Management in Severe Asthma for Adults,” CHEST Journal, chestnet.org.}

Increasing Diagnosis of Severe and Eosinophilic Asthma Redefines Market Ceiling

Increasing recognition of severe and eosinophilic asthma is creating higher-value treatment opportunities within the bronchial spasm market. The 2025 CHEST guideline described the use of anti-IL-5 agents and IL-4 receptor antagonists for patients with severe asthma. Biomarker testing identifies patients with elevated eosinophils, FeNO, or IgE who may qualify for targeted therapies. Although these therapies address a smaller patient population, they support higher treatment value per patient and can reach patients faster through FDA Priority Review and EMA accelerated assessment pathways.

Greater Use of Connected Inhalers and Home-Based Respiratory Care Reshapes Adherence Economics

Connected inhalers and home-based care are gaining importance in the bronchial spasm market as poor adherence remains common in chronic respiratory conditions. In September 2025, Adherium reported that its iCARE study included up to 2,500 asthma and COPD patients across five Intermountain Health facilities using 4,000 Hailie Smartinhalers. The results showed strong adherence and sustained patient engagement. Device-generated data can help clinicians identify changes in medication use early, reduce acute episodes, and support payer evaluations of remote respiratory management.

Inhaler-Use Errors and Treatment-Adherence Gaps Suppress Therapeutic Outcomes

Inhaler technique errors and adherence gaps remained material constraints for the bronchial spasm market. A 2025 review of connected inhaler data found that high reliever use predicted COPD exacerbations, although routine care often missed these indicators. Incorrect use reduced the effectiveness of controller and rescue medicines, even when prescriptions were filled, leading to avoidable acute care utilization. Manufacturers and providers must support medicine access with patient education, device guidance, and appropriate follow-up.

Unequal Availability of Essential Inhaled Medicines Caps Geographic Expansion

Unequal availability of inhaled medicines limited the bronchial spasm market’s reach among high-burden populations. The Global Initiative for Asthma reported in 2025 that essential inhaled medicines remained unavailable across many low- and middle-income settings. In Nigeria, salbutamol originator brands cost 11.8 times the international reference price, while the lowest-priced generic cost 5.3 times the reference price. India’s Jan Aushadhi program demonstrated that government channels lowered inhaled bronchodilator costs for eligible patients; however, supply interruptions and regional access gaps persisted, keeping treatment demand below the level indicated by disease burden.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Bronchial Spasm Market Segment Analysis

Bronchodilators held 52.56% of total treatment revenue in 2025, supported by their broad use in rapid symptom relief and long-term maintenance. Short-acting beta-2 agonists remain critical for acute bronchospasm management, while long-acting beta-2 agonists support maintenance regimens. Anticholinergics maintain an established role, particularly for COPD-associated bronchospasm. This broad treatment base drives demand across primary care, specialist care, and acute-care settings.

Corticosteroids are the fastest-growing treatment category, with this segment projected to expand at a 9.15% CAGR through 2031. Growth is supported by greater recognition of eosinophilic and T2-high asthma and the use of inhaled corticosteroids with targeted add-on therapies. The 2025 CHEST guideline issued by the American College of Chest Physicians includes anti-IL-5 therapies and IL-4 receptor antagonists for severe asthma management. Combination inhalers and biologics also increase the importance of clinical evidence, eligibility testing, and reimbursement support.

Inhalational delivery accounted for 47.76% of total treatment revenue in 2025, supported by rapid onset and direct pulmonary delivery. Metered-dose inhalers and dry-powder inhalers remain the leading device formats. GSK stated that 300 million salbutamol metered-dose inhalers are dispensed each year globally. Manufacturers are also reducing the environmental impact of inhaler propellants. AstraZeneca received approval in 2025 for Trixeo Aerosphere in the United Kingdom using HFO-1234ze(E), a propellant with 99.9% lower global warming potential than current propellants.

Oral administration is projected to grow at an 8.80% CAGR through 2031, the fastest rate among routes in the bronchial spasm market. Demand is increasing for systemic treatments that target inflammatory pathways not addressed by inhaled therapies. Injectable biologics, included within this route category, are changing the treatment mix for severe asthma. Intravenous administration remains relevant in emergency and hospital settings, while nebulizer performance and aerosol quality standards continue to influence hospital purchasing decisions and device specifications.

Adult patients accounted for 58.66% of total treatment revenue in 2025, reflecting higher diagnosis rates and medicine spending among working-age and middle-aged adults. Older adults also contribute substantial treatment volume due to declining pulmonary function and a higher prevalence of comorbidities. Complex medication regimens can limit treatment options in geriatric care. Adults, therefore, remain the largest value group across routine inhaler use and advanced treatment pathways.

Pediatric patients are forecast to grow at a 10.45% CAGR through 2031, making this the fastest-growing age group in the bronchial spasm market. A 2025 study of FDA-approved ProAir Digihaler use in a pediatric inner-city population found that digital feedback improved inhalation technique. AstraZeneca received FDA approval for BREZTRI Aerosphere in April 2026, extending asthma eligibility to patients aged 12 years and older. Brazil incorporated benralizumab and dupilumab into its public health system in January 2025, covering patients aged 6-17 years with severe eosinophilic asthma.

Hospitals held 62.88% of total treatment revenue in 2025 because they manage acute episodes and often initiate biologic therapy. Severe exacerbations may require emergency care, intensive monitoring, or specialist assessment. Hospitals also document treatment history required for payer authorization processes. Specialty clinics support spirometry, adherence counseling, and treatment-plan adjustments, while emergency departments and other acute-care facilities generate additional demand for rescue therapies.

Homecare settings are forecast to expand at a 9.56% CAGR through 2031 in the bronchial spasm market. Connected inhalers, remote monitoring, and less frequent biologic dosing can reduce clinic visits for stable patients. Adherium’s 2025 iCARE study supported remote monitoring across five Intermountain Health facilities. Home-based care enables medication-use monitoring between appointments and will gain importance where providers and payers support long-term care outside hospital settings.

Geography Analysis

North America Bronchial Spasm Market

North America held 42.44% of total treatment revenue in 2025, making it the largest regional contributor. The United States had 27 million asthma patients and nearly 10 million asthma attacks annually. AstraZeneca launched BREZTRI Aerosphere for asthma in the United States in July 2026, following FDA approval on April 28, 2026. Chiesi’s TRIMBOW was approved for the maintenance treatment of asthma in adults in May 2026.

Europe Bronchial Spasm Market

Europe was the second-largest region in the bronchial spasm market. Its healthcare systems provided broad access to respiratory treatments, although tendering and generic substitution pressured originator prices. The WHO European Region reported USD 20.7 billion in productivity losses from chronic respiratory diseases among people aged 30–74 years. Chiesi received European Commission authorization for its NEXThaler single-inhaler triple therapy for adults with asthma on July 31, 2026. Germany, the United Kingdom, France, Italy, and Spain accounted for a significant share of the region’s treatment volume.

APAC and South America Bronchial Spasm Market

Asia-Pacific is forecast to expand at a CAGR of 10.88% through 2031, the fastest growth rate in the bronchial spasm market. China and India are central to this growth due to their substantial respiratory disease burden. GSK’s Trelegy Ellipta received approval from China’s National Medical Products Administration for adult asthma on January 23, 2026. GSK stated that China had 46 million adults with asthma. India’s Jan Aushadhi program is expanding access to lower-cost inhalers, while Brazil’s 2025 public-system decisions and Chile’s December 2025 biologic coverage under GES broadened access in South America.